Logo

Pfizer's Prevnar 20 (Pneumococcal 20-Valent Conjugate Vaccine) Receives the CDC's Advisory Committee Recommendation for Invasive Disease and Pneumonia

Share this
Pfizer's Prevnar 20 (Pneumococcal 20-Valent Conjugate Vaccine) Receives the CDC's Advisory Committee Recommendation for Invasive Disease and Pneumonia

Pfizer's Prevnar 20 (Pneumococcal 20-Valent Conjugate Vaccine) Receives the CDC's Advisory Committee Recommendation for Invasive Disease and Pneumonia

Shots:

  • The CDC’s ACIP has voted to recommend Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) to protect adults against invasive disease and pneumonia caused by the 20 S. pneumoniae serotypes
  • The ACIP has recommended one dose of Prevnar 20 for adults aged ≥65 & for ≥19yrs. with risk conditions who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown. If PCV15 is used- it should be followed by a dose of PPSV23
  • On June 8- 2021- the US FDA has approved Prevnar 20 for the prevention of invasive disease and pneumonia in adults aged ≥18yrs. and Prevnar 20 is currently under EMA’s CHMP review

Click here ­to­ read full press release/ article | Ref: Pfizer | Image: The Wall Street Journal


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family